$10995 | Single User
$21990 | Site License
$32985 | Enterprise License

PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024
[Published by Global Data]

Published by Global Data: 10 Sep 2015 | 17095 | In Stock

Introduction

PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024

Summary

Multiple Sclerosis (MS) is an inflammatory autoimmune disease of the central nervous system which leads to neurological disability. The exact underlying cause of the disease is poorly understood; however, it appears to involve a complex combination of genetic susceptibility and a non-genetic trigger. The MS therapeutics market has entered an exciting phase, with an upsurge of available treatment options. Over the forecast period, patients are expected to continue to switch to the oral disease-modifying therapies (DMTs), lessening the stronghold of the established injectable treatments. There are also several promising products in the late-stage pipeline, with a diverse range of mechanisms offering clinical advantages intended to address unmet needs. Both pipeline and marketed DMTs are seeking approval for the treatment of progressive MS, which currently represents a significant unmet need. These factors are expected to increase treatment rates throughout the 10MM resulting, driving market growth. However, this will be largely offset by brand erosion due to the emergence of biosimilars and generic small molecules.

Highlights

Key Questions Answered

- The MS market has experienced a paradigm shift with the launch of first-line oral DMTs and efficacious escalation therapies. In light of this, what are the current clinical and environmental unmet needs? Will there be opportunities in this market for drug developers throughout the forecast period?

- The current late-stage MS pipeline is robust and diverse, with 13 products in Phase III. GlobalData has profiled nine DMT drug therapies, of which eight are anticipated to launch during the forecast period. What impact will these drugs have on the market? How will they affect the treatment algorithm for MS? Will these drugs fulfil any of the unmet needs for MS?

- The diagnosis and management of MS is challenging, even for the most experienced neurologists. How does the diagnosis and management of MS differ amongst the 10MM? Which DMT treatments are most commonly prescribed in each market, and how will prescribing patterns change over the forecast period?

Key Findings

- The main driver of growth in the MS market will be the introduction of novel DMT products over the forecast period. Drugs targeting clinical unmet needs; such as improved efficacy, more convenient administration, or progressive MS approval; will increase treatment rates and drive market growth.

- There is a high disparity between treatments for RRMS and progressive MS amongst the currently available drugs and, despite its diversity, the late late-stage pipeline remains skewed towards RRMS. As such, the RRMS market will become increasingly competitive making it more difficult for new entrants to gain patient share.

- The biggest barrier for growth in the MS market will be competition from generic/biosimilar products for key branded therapies. In particular, the launch of generic small-molecules will hamper future growth of the MS market.

- Considerable opportunity remains for products that meet the unmet needs in the MS market. A drug that prevents disease progression and the accumulation of disability would be viewed favourably. Additionally, targeting progressive MS will be an ongoing opportunity.

Scope

- Overview of MS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

- Annualized MS market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.

- Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the MS therapeutics market.

- Pipeline analysis: focus on nine late-stage pipeline MS drugs, discussing emerging trends as well as an overview of earlier phase drugs and a top-line analysis of therapeutic vaccines.

- Analysis of the current and future market competition in the global MS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

- Develop business strategies by understanding the trends shaping and driving the global MS therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MS therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Track drug sales in the global MS therapeutics market from 2014-2024.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents
for PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024 [Published by Global Data]

  • 1 Table of Contents

    1 Table of Contents 10

    1.1 List of Tables 17

    1.2 List of Figures 23

    2 Introduction 25

    2.1 Catalyst 25

    2.2 Related Reports 26

    3 Disease Overview 27

    3.1 Etiology and Pathophysiology 27

    3.1.1 Etiology 27

    3.1.2 Pathophysiology 28

    3.2 Classification 29

    3.2.1 Relapse-Remitting Multiple Sclerosis 29

    3.2.2 Secondary Progressive Multiple Sclerosis 30

    3.2.3 Primary Progressive Multiple Sclerosis 30

    3.2.4 Progressive Relapsing Multiple Sclerosis 30

    3.3 Symptoms 31

    3.4 Prognosis 32

    3.5 Quality of Life 33

    4 Epidemiology 34

    4.1 Disease Background 34

    4.2 Risk Factors and Comorbidities 35

    4.2.1 Family members of MS patients have a 1-5% risk of developing MS 36

    4.2.2 Women are twice as likely to develop MS, but men have a worse prognosis 37

    4.2.3 Caucasians have a higher risk of MS than any other race/ethnicity 37

    4.2.4 Protective effect of vitamin D on MS may relate to latitude and month of birth 37

    4.2.5 Timing of environmental exposures affects MS risk 38

    4.2.6 Exposure to smoking may increase MS risk and worsen prognosis 38

    4.2.7 Autoimmune Disease Comorbidities of MS 39

    4.2.8 Mental comorbidities are found in up to 60% of MS patients and may affect relapse rates 39

    4.3 Global Trends 40

    4.3.1 North America 40

    4.3.2 Europe 41

    4.3.3 Asia 41

    4.4 Forecast Methodology 42

    4.4.1 Sources Used 45

    4.4.2 Sources Not Used 51

    4.4.3 Forecast Assumptions and Methods 51

    4.5 Epidemiological Forecast of Multiple Sclerosis (2014-2024) 58

    4.5.1 Diagnosed Prevalent Cases of MS 58

    4.5.2 Age-Specific Diagnosed Prevalent Cases of MS 60

    4.5.3 Sex-Specific Diagnosed Prevalent Cases of MS 62

    4.5.4 Diagnosed Incident Cases of MS 64

    4.5.5 Age-Specific Diagnosed Incident Cases of MS 66

    4.5.6 Sex-Specific Diagnosed Incident Cases of MS 68

    4.5.7 MS Subtypes 69

    4.6 Discussion 70

    4.6.1 Epidemiological Forecast Insight 70

    4.6.2 Limitations of the Analysis 71

    4.6.3 Strengths of the Analysis 71

    5 Disease Management 72

    5.1 Diagnosis 72

    5.2 Treatment Overview 76

    5.2.1 Management of Acute Relapse 78

    5.2.2 Treatment with Disease-Modifying Therapies 78

    5.2.3 Symptomatic Therapies 83

    5.3 US 84

    5.3.1 Diagnosis 84

    5.3.2 Drug Treatment 85

    5.4 France 89

    5.4.1 Diagnosis 89

    5.4.2 Drug Treatment 90

    5.5 Germany 92

    5.5.1 Diagnosis 92

    5.5.2 Drug Treatment 93

    5.6 Italy 95

    5.6.1 Diagnosis 95

    5.6.2 Drug Treatment 96

    5.7 Spain 98

    5.7.1 Diagnosis 98

    5.7.2 Drug Treatment 99

    5.8 UK 101

    5.8.1 Diagnosis 101

    5.8.2 Drug Treatment 102

    5.9 Japan 104

    5.9.1 Diagnosis 104

    5.9.2 Drug Treatment 105

    5.10 Canada 107

    5.10.1 Diagnosis 107

    5.10.2 Drug Treatment 108

    5.11 China 110

    5.11.1 Diagnosis 110

    5.11.2 Drug Treatment 111

    5.12 India 113

    5.12.1 Diagnosis 113

    5.12.2 Drug Treatment 114

    6 Competitive Assessment 116

    6.1 Overview 116

    6.2 Product Profiles - Major Injectable Brands 118

    6.2.1 Betaseron 118

    6.2.2 Avonex 123

    6.2.3 Rebif 128

    6.2.4 Copaxone 132

    6.2.5 Tysabri 138

    6.2.6 Lemtrada 143

    6.2.7 Plegridy 150

    6.3 Product Profiles - Major Small Molecule Brands 156

    6.3.1 Gilenya 156

    6.3.2 Aubagio 162

    6.3.3 Tecfidera 167

    6.4 Other Disease-Modifying Therapies 173

    6.4.1 Overview 173

    7 Unmet Need and Opportunity 175

    7.1 Overview 175

    7.2 Curative Therapies 176

    7.2.1 Unmet Need 176

    7.2.2 Gap Analysis 177

    7.2.3 Opportunity 178

    7.3 The High Cost of MS Drugs 179

    7.3.1 Unmet Need 179

    7.3.2 Gap Analysis 180

    7.3.3 Opportunity 181

    7.4 Safety and Tolerability of Therapy 181

    7.4.1 Unmet Need 181

    7.4.2 Gap Analysis 182

    7.4.3 Opportunity 183

    7.5 Effective Treatments for Progressive MS 183

    7.5.1 Unmet Need 183

    7.5.2 Gap Analysis 185

    7.5.3 Opportunity 185

    7.6 Inconvenient Route of Administration and Frequent Dosing 186

    7.6.1 Unmet Need 186

    7.6.2 Gap Analysis 187

    7.6.3 Opportunity 187

    7.7 MS Biomarkers for Early Diagnosis and Treatment Choice 187

    7.7.1 Unmet Need 187

    7.7.2 Gap Analysis 189

    7.7.3 Opportunity 189

    8 Pipeline Assessment 191

    8.1 Overview 191

    8.2 Clinical Trial Mapping 191

    8.2.1 Clinical Trials by Country 191

    8.3 Promising Drugs in Clinical Development 192

    8.3.1 Zinbryta 195

    8.3.2 Ocrelizumab 203

    8.3.3 Ofatumumab 210

    8.3.4 Opicinumab 216

    8.3.5 Nerventra 221

    8.3.6 Masitinib 228

    8.3.7 Siponimod 233

    8.3.8 Ozanimod 239

    8.3.9 Ponesimod 243

    8.4 Late-Stage Therapeutic Vaccines 249

    8.4.1 NeuroVax 250

    8.4.2 Tcelna 253

    8.5 Other Drugs in Development 257

    9 Current and Future Players 260

    9.1 Overview 260

    9.2 Trends in Corporate Strategy 262

    9.3 Company Profiles 263

    9.3.1 Biogen 263

    9.3.2 Teva 266

    9.3.3 Merck Serono (EMD Serono) 269

    9.3.4 Sanofi (Genzyme) 271

    9.3.5 Bayer 274

    9.3.6 Novartis 277

    9.3.7 Roche 280

    10 Market Outlook 283

    10.1 Global Markets 283

    10.1.1 Forecast 283

    10.1.2 Drivers and Barriers — Global Issues 289

    10.2 United States 290

    10.2.1 Forecast 290

    10.2.2 Key Events 294

    10.2.3 Drivers and Barriers 295

    10.3 5EU 295

    10.3.1 Forecast 295

    10.3.2 Key Events 301

    10.3.3 Drivers and Barriers 302

    10.4 Japan 302

    10.4.1 Forecast 302

    10.4.2 Key Events 306

    10.4.3 Drivers and Barriers 307

    10.5 Canada 307

    10.5.1 Forecast 307

    10.5.2 Key Events 312

    10.5.3 Drivers and Barriers 313

    10.6 China 313

    10.6.1 Forecast 313

    10.6.2 Key Events 317

    10.6.3 Drivers and Barriers 317

    10.7 India 318

    10.7.1 Forecast 318

    10.7.2 Key Events 321

    10.7.3 Drivers and Barriers 321

    11 Appendix 322

    11.1 Bibliography 322

    11.2 Abbreviations 344

    11.3 Methodology 349

    11.4 Forecasting Methodology 349

    11.4.1 Diagnosed MS Patients 349

    11.4.2 Percent Drug-Treated Patients 349

    11.4.3 Launch and Patent Expiry Dates 350

    11.4.4 General Pricing Assumptions 351

    11.4.5 Individual Drug Assumptions 352

    11.4.6 Generic Erosion 358

    11.4.7 Pricing of Pipeline Agents 358

    11.5 Primary Research — KOLs Interviewed for this Report 360

    11.6 Primary Research — Prescriber Survey 363

    11.7 About the Authors 364

    11.7.1 Analyst 364

    11.7.2 Therapy Area Director 364

    11.7.3 Epidemiologist 365

    11.7.4 Global Director of Therapy Research and Analysis 365

    11.8 About GlobalData 366

    11.9 Disclaimer 366

List Of Tables
in PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024 [Published by Global Data]

1.1 List of Tables

Table 1: Common Presenting Symptoms of MS 32

Table 2: Factors That Can Affect Prognosis in MS 33

Table 3: Risk Factors and Comorbidities for MS 36

Table 4: Sources of MS Diagnosed Prevalence and Diagnosed Incidence Data Used in the Epidemiology Forecast 44

Table 5: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024 59

Table 6: 10MM, Diagnosed Prevalent Cases of MS, by Age, Men and Women, N (Row %), 2014 61

Table 7: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, by Sex, N (Row %), 2014 63

Table 8: 10MM, Diagnosed Incident Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024 65

Table 9: 10MM, Diagnosed Incident Cases of MS, by Age, Men and Women, N (Row %), 2014 67

Table 10: 10MM, Diagnosed Incident Cases of MS, by Sex, N (Row %), 2014 68

Table 11: Revised 2010 McDonald Criteria for the Diagnosis of MS 75

Table 12: Treatment Guidelines for MS 77

Table 13: Top Three Disease-Modifying Therapies Prescribed for MS by Market 81

Table 14: Pharmacotherapy for Common MS Symptoms 83

Table 15: US - MS Diagnosis Metrics 85

Table 16: US - MS Treatment Metrics 89

Table 17: France - MS Diagnosis Metrics 90

Table 18: France - MS Treatment Metrics 92

Table 19: Germany - MS Diagnosis Metrics 93

Table 20: Germany - MS Treatment Metrics 95

Table 21: Italy - MS Diagnosis Metrics 96

Table 22: Italy - MS Treatment Metrics 97

Table 23: Spain - MS Diagnosis Metrics 98

Table 24: Spain - MS Treatment Metrics 101

Table 25: UK - MS Diagnosis Metrics 102

Table 26: UK - MS Treatment Metrics 104

Table 27: Japan - MS Diagnosis Metrics 105

Table 28: Japan - MS Treatment Metrics 106

Table 29: Canada - MS Diagnosis Metrics 108

Table 30: Canada - MS Treatment Metrics 110

Table 31: China - MS Diagnosis Metrics 111

Table 32: China - MS Treatment Metrics 113

Table 33: India - MS Diagnosis Metrics 114

Table 34: India - MS Treatment Metrics 115

Table 35: Leading Disease-Modifying Drugs for the Treatment of MS, 2015 118

Table 36: Product Profile — Betaseron 120

Table 37: Betaseron SWOT Analysis, 2015 122

Table 38: Global Sales Forecasts ($m) for Betaseron, 2014-2024 123

Table 39: Product Profile — Avonex 124

Table 40: Avonex SWOT Analysis, 2015 126

Table 41: Global Sales Forecasts ($m) for Avonex, 2014-2024 127

Table 42: Product Profile — Rebif 129

Table 43: Rebif SWOT Analysis, 2014 131

Table 44: Global Sales Forecasts ($m) for Rebif, 2014-2024 132

Table 45: Product Profile — Copaxone 134

Table 46: Copaxone SWOT Analysis, 2015 136

Table 47: Global Sales Forecasts ($m) for Copaxone, 2014-2024 137

Table 48: Product Profile — Tysabri 140

Table 49: Tysabri SWOT Analysis, 2015 142

Table 50: Global Sales Forecasts ($m) for Tysabri, 2014-2024 143

Table 51: Product Profile — Lemtrada 146

Table 52: Lemtrada SWOT Analysis, 2015 149

Table 53: Global Sales Forecasts ($m) for Lemtrada, 2014-2024 150

Table 54: Product Profile — Plegridy 151

Table 55: Clinical and MRI Endpoints at Year 1 from a Phase III Trial of Plegridy in MS 152

Table 56: Clinical and MRI Endpoints at Year 2 from a Phase III Trial of Plegridy in MS 153

Table 57: Adverse Events During Year 1 of a Phase III Trial of Plegridy in MS 154

Table 58: Plegridy SWOT Analysis, 2015 155

Table 59: Global Sales Forecasts ($m) for Plegridy, 2014-2024 156

Table 60: Product Profile — Gilenya 158

Table 61: Gilenya SWOT Analysis, 2015 160

Table 62: Global Sales Forecasts ($m) for Gilenya, 2014-2024 161

Table 63: Product Profile — Aubagio 163

Table 64: Aubagio SWOT Analysis, 2015 166

Table 65: Global Sales Forecasts ($m) for Aubagio, 2014-2024 167

Table 66: Product Profile — Tecfidera 169

Table 67: Tecfidera SWOT Analysis, 2015 171

Table 68: Global Sales Forecasts ($m) for Tecfidera, 2014-2024 173

Table 69: Summary of Alternative MS DMTs, 2014 174

Table 70: Unmet Need and Opportunity in MS 176

Table 71: Product Profile — Zinbryta High-Yield Process 197

Table 72: Adverse Events during Year 1 of a Phase III trial of Zinbryta in MS 199

Table 73: Zinbryta SWOT Analysis, 2015 202

Table 74: Global Sales Forecasts ($m) for Zinbryta, 2014-2024 203

Table 75: Product Profile — Ocrelizumab 205

Table 76: Ocrelizumab SWOT Analysis, 2015 209

Table 77: Global Sales Forecasts ($m) for ocrelizumab, 2014-2024 210

Table 78: Product Profile — Ofatumumab 211

Table 79: Ofatumumab SWOT Analysis, 2015 215

Table 80: Global Sales Forecasts ($m) for Ofatumumab, 2014-2024 216

Table 81: Product Profile — Opicinumab 217

Table 82: Opicinumab SWOT Analysis, 2015 220

Table 83: Product Profile — Nerventra 223

Table 84: Nerventra SWOT Analysis, 2015 227

Table 85: Global Sales Forecasts ($m) for Nerventra, 2014-2024 228

Table 86: Product Profile - Masitinib 229

Table 87: Masitinib SWOT Analysis, 2015 232

Table 88: Global Sales Forecasts ($m) for Masitinib, 2014-2024 233

Table 89: Product Profile — Siponimod 234

Table 90: Siponimod SWOT Analysis, 2015 237

Table 91: Global Sales Forecasts ($m) for siponimod, 2014-2024 238

Table 92: Product Profile — Ozanimod 240

Table 93: Ozanimod SWOT Analysis, 2015 242

Table 94: Global Sales Forecasts ($m) for Ozanimod, 2014-2024 243

Table 95: Product Profile — Ponesimod 244

Table 96: Efficacy Results for Ponesimod in a Phase IIb MS Trial 245

Table 97: Ponesimod SWOT Analysis, 2015 248

Table 98: Global Sales Forecasts ($m) for Ponesimod, 2014-2024 249

Table 99: Product Profile — NeuroVax 251

Table 100: NeuroVax SWOT Analysis, 2015 253

Table 101: Product Profile — Tcelna 255

Table 102: Tcelna SWOT Analysis, 2015 257

Table 103: Drugs in Development, 2015 258

Table 104: Key Companies in the MS Market, 2015 261

Table 105: Biogen’s Multiple Sclerosis Portfolio Assessment, 2015 265

Table 106: Biogen SWOT Analysis, 2015 266

Table 107: Teva’s MS Portfolio Assessment, 2015 268

Table 108: Teva SWOT Analysis, 2015 268

Table 109: Merck’s Multiple Sclerosis Portfolio Assessment, 2015 270

Table 110: Merck SWOT Analysis, 2015 271

Table 111: Sanofi’s Multiple Sclerosis Portfolio Assessment, 2015 273

Table 112: Sanofi SWOT Analysis, 2015 274

Table 113: Bayer’s MS Portfolio Assessment, 2015 276

Table 114: Bayer SWOT Analysis, 2015 276

Table 115: Novartis’ MS Portfolio Assessment, 2015 279

Table 116: Novartis SWOT Analysis, 2015 280

Table 117: Roche’s Multiple Sclerosis Portfolio Assessment, 2015 282

Table 118: Roche SWOT Analysis, 2015 282

Table 119: Global Sales Forecast ($m) for MS, 2014-2024 286

Table 120: Global MS Market — Drivers and Barriers, 2014-2024 289

Table 121: Sales Forecast ($m) for MS in the United States, 2014-2024 292

Table 122: Key Events Impacting Sales for MS in the US, 2014-2024 294

Table 123: MS Market in the US — Drivers and Barriers, 2014-2024 295

Table 124: Sales Forecasts ($m) for MS in the 5EU, 2014-2024 299

Table 125: Key Events Impacting Sales for MS in the 5EU, 2014-2024 301

Table 126: MS Market in the 5EU — Drivers and Barriers, 2014-2024 302

Table 127: Sales Forecasts ($m) for MS in the Japan, 2014-2024 304

Table 128: Key Events Impacting Sales for MS in Japan, 2014-2024 306

Table 129: MS Market in Japan — Drivers and Barriers, 2014-2024 307

Table 130: Sales Forecasts ($m) for MS in the Canada, 2014-2024 310

Table 131: Key Events Impacting Sales for MS in Canada, 2014-2024 312

Table 132: MS Market in Canada — Drivers and Barriers, 2014-2024 313

Table 133: Sales Forecasts ($m) for MS in the China, 2014-2024 315

Table 134: Key Events Impacting Sales for MS in China, 2014-2024 317

Table 135: MS Market in China — Drivers and Barriers, 2014-2024 317

Table 136: Sales Forecasts ($m) for MS in the India, 2014-2024 319

Table 137: Key Events Impacting Sales for MS in India, 2014-2024 321

Table 138: MS Market in India — Drivers and Barriers, 2014-2024 321

Table 139: Key Launch Dates 350

Table 140: Key Patent Expiries 350

Table 141: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country 363

List Of Figures, Charts and Diagrams
in PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024 [Published by Global Data]

1.2 List of Figures

Figure 1: Accrual of Disability in the Four Subtypes of MS 31

Figure 2: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024 60

Figure 3: 10MM, Diagnosed Prevalent Cases of MS, by Age, Men and Women, N, 2014 62

Figure 4: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, by Sex, N, 2014 64

Figure 5: 10MM, Diagnosed Incident Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024 66

Figure 6: 10MM, Diagnosed Incident Cases of MS, by Age, Men and Women, N, 2014 67

Figure 7: 10MM, Diagnosed Incident Cases of MS, by Sex, N, 2014 69

Figure 8: 10MM, MS Subtype Distributions, %*, 2014 70

Figure 9: Expanded Disability Status Scale (EDSS) 76

Figure 10: Algorithm for the Treatment of MS with Disease-Modifying Therapies 82

Figure 11: MS Therapeutics — Clinical Trials by Country, 2015 192

Figure 12: Multiple Sclerosis — Phase II-III Pipeline, 2015 194

Figure 13: Competitive Assessment of Late-Stage Pipeline Agents in MS, 2014-2024 195

Figure 14: Multiple Sclerosis — Phase II-III Therapeutic Vaccines, 2015 250

Figure 15: Company Portfolio Gap Analysis in MS, 2014-2024 262

Figure 16: Global Sales for MS by Region, 2014-2024 287

Figure 17: Global Sales for MS by Therapy Type, 2014-2024 288

Figure 18: Sales for MS in the United States by Therapy Type, 2014-2024 293

Figure 19: Sales for MS in the 5EU by Therapy Type, 2014-2024 300

Figure 20: Sales for MS in Japan by Therapy Type, 2014-2024 305

Figure 21: Sales for MS in Canada by Therapy Type, 2014-2024 311

Figure 22: Sales for MS in China by Therapy Type, 2014-2024 316

Figure 23: Sales for MS in India by Drug Class, 2014-2024 320

Additional Details

Publisher

Global Data

Publisher Information

Reference

17095 | GDHC89PIDR

Number of Pages

367

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025
PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025SummaryGlobalData estim...
01 May 2016 by Global Data USD $10,995 More Info
PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023
PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023SummaryRenal cel...
21 Apr 2016 by Global Data USD $10,995 More Info
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024SummaryPsoriasis (PsO) is a...
13 Apr 2016 by Global Data USD $10,995 More Info
PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024SummaryBipolar disor...
01 Mar 2016 by Global Data USD $10,995 More Info
PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024...
01 Jan 2016 by Global Data USD $10,995 More Info
PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024
PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024SummaryDry Eye Syn...
05 Nov 2015 by Global Data USD $10,995 More Info
PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2024SummaryAlthough the...
03 Nov 2015 by Global Data USD $10,995 More Info
PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023
PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023SummaryThe Multiple ...
01 Nov 2015 by Global Data USD $10,995 More Info
PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024SummaryIn t...
01 Oct 2015 by Global Data USD $10,995 More Info
PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024SummaryAllergic Rhi...
01 Sep 2015 by Global Data USD $10,995 More Info

This report is published by Global Data

Download Free Report Summary PDF

PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024 [Published by Global Data] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...